/
BMEA
$1.39+$0.07 (+5.30%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$95.4M
72M shares
52-week range
$0.87 – $2.99
24% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.99%
Moderate
Price (6 mo)
Loading chart…
Change$-14.01
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $132.0K | $0 | $0 | $0 | $0 | $1.4M |
| Gross profit | $0 | −$132.0K | $0 | $0 | $0 | $0 | −$1.4M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $1.1M | $3.7M | $28.0M | $62.7M | $102.5M | $118.1M | $62.0M |
| Operating income | −$1.2M | −$5.3M | −$41.7M | −$83.6M | −$126.1M | −$144.1M | −$81.3M |
| EBITDA | −$1.2M | −$5.2M | −$41.3M | −$81.1M | −$115.7M | −$136.7M | −$60.4M |
| Net income | −$1.2M | −$5.3M | −$41.6M | −$81.8M | −$117.3M | −$138.4M | −$61.8M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.11 | -0.50 | -1.74 | -2.80 | -3.44 | -3.83 | -1.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.87 | $-1.17–$-0.73 | 5 |
| 2027 | $1M | $-1.19 | $-2.36–$-0.64 | 4 |
| 2028 | $5M | $-1.07 | $-1.13–$-0.98 | 3 |
| 2029 | $616M | $-0.80 | $-0.80–$-0.80 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.98
Price
$1.39
Implied downside
-30%
Peer comparison
Biomea Fusion, Inc. Common Stock
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
www.biomeafusion.com- Employees
- 40
- IPO / List date
- Apr 16, 2021
- HQ
- SAN CARLOS, CA
Held by traders on TradeandTell
No one on the platform currently holds BMEA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,312,798 | $2.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BMEA yet.
